Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort

Hepatology Research

Volumn 42, Issue 12, 2012, Pages 1175-1186

  Thein, Hla Hla ^a,d,e   Walter, Scott R ^a   Gidding, Heather F ^a   Amin, Janaki ^a   Law, Matthew G ^a   George, Jacob ^b   Dore, Gregory J ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Australia; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Survival; Treatment outcome

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER THERAPY; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

EID: 84870284529     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01037.x     Document Type: Article

References (41)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43.
4. Chen TH-H, Chen C-J, Yen M-F etal. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002; 98: 257-61.
5. Tsukuma H, Hiyama T, Tanaka S etal. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
6. Velazquez RF, Rodriguez M, Navascues CA etal. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520-7.
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
8. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-54.
9. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-8.
10. Okuda K, Ohtsuki T, Obata H etal. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
11. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-83.
12. Arii S, Yamaoka Y, Futagawa S etal. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
13. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
14. Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol 2004; 11: 298-303.
15. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
16. Tseng PL, Wang JH, Tung HD etal. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol 2010; 25: 1426-34.
17. Zaydfudim V, Whiteside MA, Griffin MR, Feurer ID, Wright JK, Pinson CW. Health insurance status affects staging and influences treatment strategies in patients with hepatocellular carcinoma. Ann Surg Oncol 2010; 17: 3104-11.
18. Amin J, Dore GJ, O'Connell DL etal. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006; 45: 197-203.
19. Amin J, O'Connell D, Bartlett M etal. Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study. Aust N Z J Public Health 2007; 31: 475-82.
20. Australian Bureau of Statistics. Drug-Induced Deaths - a Guide to ABS Causes of Death Data. Cat. No. 4809.0.55.001. Canberra: Australian Bureau of Statistics, 2002.
21. CHeReL. The Centre for Health Record Linkage. Available at: http://www.cherel.org.au. Accessed March 1, 2010.
22. ChoiceMaker Technologies. ChoiceMaker software. New York, USA.
23. Australian Bureau of Statistics. Australian Historical Population Statistics 2008, Cat. No. 3105.0.65.001. Canberra: Australian Bureau of Statistics, 2008; In.
24. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
25. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
26. Thomas MB, Jaffe D, Choti MM etal. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28: 3994-4005.
27. Autralian Bureau of Statistics. Australian Standard Geographical Classification (ASGC) Concordances. Cat. No. 1216.0.15.002. Canberra: ABS, 2006.
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
29. Quan H, Sundararajan V, Halfon P etal. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
30. Bull K, Spiegelhalter DJ. Survival analysis in observational studies. Stat Med 1997; 16: 1041-74.
31. El-Serag HB, Siegel AB, Davila JA etal. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44: 158-66.
32. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.
33. Artinyan A, Mailey B, Sanchez-Luege N etal. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010; 116: 1367-77.
34. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
35. Gellert L, Jalaludin B, Levy M. Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. Intern Med J 2007; 37: 516-22.
36. Takenaka K, Yamamoto K, Taketomi A etal. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1995; 22: 20-4.
37. Miyagawa S, Kawasaki S, Makuuchi M. Comparison of the characteristics of hepatocellular carcinoma between hepatitis B and C viral infection: tumor multicentricity in cirrhotic liver with hepatitis C. Hepatology 1996; 24: 307-10.
38. Roayaie S, Haim MB, Emre S etal. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. Ann Surg Oncol 2000; 7: 764-70.
39. Chen CH, Huang GT, Yang PM etal. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006; 42: 2524-9.
40. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001; 22: 91-113.
41. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer 2005; 92: 241-5.